That sounds like a very solid theory, Nader did make the point that this is a worldwide drug. I think he is opening up the narrow thought that the obvious step is to the nasdaq or some other us market, uplisting to some international market could make sense. I also don’t think the partner is some large pharma, they tend to want to take a controlling position in these deals and this is a low upfront with a large % of future business for cytodyn. A mid size or smaller company does not nessesarily have the billions it would take to own a chunk of the company but would be willing to give up a lot of profit to get a foothold in the hiv market. It also sounds like the other markets beyond the us are deals with other companies, so not a big pharma type deal for all markets. It would be strange that a Chinese company made a deal for the us market but maybe that is the story.